A multi-institutional team led by The University of Osaka developed a chimeric antigen receptor (CAR) T cell-based strategy ...

More information: Rebekka Wegmann et al, Single-cell landscape of innate and acquired drug resistance in acute myeloid ...

and cell death. Abnormalities in tyrosine kinases are common in AML, and constitute an attractive therapeutic target. An example is given by the balanced chromosomal translocations (TEL-Abl ...

be able to identify and kill cancer cells with the targeted antigen on their surfaces throughout the body. AML is aggressive, and there are few effective treatment options for relapsed or ...

Acute myeloid leukemia (AML) is one of the most aggressive and genetically complex cancers, marked by the unchecked growth of immature myeloid cells. Its diversity stems from numerous genetic ...

The AACR poster presentation will provide an update on the data in AML patients most recently presented at the American Society of Hematology (ASH) Annual Meeting 2024 showing that ICT01 administered ...